Ab­b­Vie gets first taste of Ela­here po­ten­tial with new mid-stage win

Ab­b­Vie’s $10.1 bil­lion pur­chase of Im­muno­Gen and ac­com­pa­ny­ing an­ti­body-drug con­ju­gate Ela­here is al­ready pay­ing off, with the drug scor­ing a new mid-stage vic­to­ry.

The Chica­go …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER